Mets' new relief ace: Newly engaged and with a rehab plan to return to mound
After snapping a few photos, some of which included their goldendoodle who wore a handkerchief that read, “Mint to be,” ...
Pharm Exec2d
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...
Targeted Oncology7d
Radium-223 Re-Treatment Deemed Safe in mCRPC
Radium-223 re-treatment is safe for metastatic castration-resistant prostate cancer, per findings from the 2025 ASCO GU ...
Managed Healthcare Executive4d
FDA Approves Second Biosimilars for Prolia/Xgeva
Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors.
centerforbiosimilars3d
FDA, EMA Approve Second Pair of Denosumab Biosimilars
The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis' ...
EurekAlert!3d
Aston University collaboration to develop injectable paste which could treat bone cancer
Aston University is collaborating in research to develop an injectable paste which could treat bone cancer. The Royal ...
Business Wire5d
FDA Approves Samsung Bioepis’ OSPOMYV™, XBRYK™ (denosumab-dssb), a Biosimilar to Prolia and Xgeva
Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for OS ...
News Medical on MSN3d
Aston University collaborates on injectable paste for bone cancer treatment
Aston University is collaborating in research to develop an injectable paste which could treat bone cancer.